LY/ICG@HES-PCL NPs have been used to deliver TGF-β inhibitors LY2157299 to tumor sites, improving and prolonging the efficacy of CAR-T cell therapy for lymphoma [119]. The gene discussed is TGFB1; the disease is lymphoma.